As the treatment paradigm shifts towards more neoadjuvant therapies in pancreatic cancer, the role of hENT1 in biopsy samples as a predictor of chemotherapy response in patients with early disease will have to be further investigated. This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.